In-vitro diagnostic tests

In July 2026, an independent review of UK pathology services was published. It covers seven main areas: international experience, the devolved UK nations, quality, workforce, patient access, digital and diagnostic infrastructure, and value and funding. Among the six system-wide priorities, the report recommends aligning digital, workforce, and funding reforms into a single implementation program, moving towards activity-aligned funding through a price-per-test tariff model.

As of July 2026, the Aragon Institute of Health Sciences (IACS), one of Spain’s regional health technology assessment bodies, is conducting several HTAs in areas including diagnostic imaging, digital health, and in vitro diagnostics.

As of July 2026, four medical technologies across e-health, diagnostic imaging, in vitro diagnostics (IVDs), men’s health, and orthopedics fields are awaiting final recommendations from the Regional HTA Commission following completion of the assessment stage within the Lombardy Regional HTA Program.

In June 2026, Health Technology Wales (HTW) accomplished one full appraisal on cone-beam computed tomography for breast imaging in people with suspected breast cancer. Additionally, three Med Tech-related Topic Exploration Reports were published in the fields of e-health and in vitro diagnostics.

On June 11, 2026, the National Association of Statutory Health Insurance Physicians (KBV) announced a number of changes to the reimbursement of human genetics tests to be introduced as of October 1, 2026. The package of changes includes, among other measures, a reduction in the reimbursement values for human genetic services and the introduction of additional volume-based reimbursement reductions at the practice level. These measures are intended to reduce expenditure on human genetic tests by 31%.

In June 2026, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned newborn screening for severe combined immunodeficiency, primary endovascular revascularization procedures for chronic limb-threatening ischemia, placental growth factor (PLGF)-based testing for suspected pre-eclampsia, and digital front door technologies before assessment for NHS Talking Therapies.

On June 9, 2026, the Swiss Federal Office of Public Health published changes to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The nearest changes will take effect on July 1, 2026, and include the introduction of the first-trimester preeclampsia screening and adjustment of the tariffs for the highest-grossing laboratory analyses (Annex 3 KLV), changes in reimbursement conditions for medical aids via the List of Medical Aids MiGel (Annex 2 KLV), as well as the expansion of the outpatient-before-inpatient policy (Annex 1a KLV) and update of coverage decisions on the List of explicitly evaluated services (Annex 1 KLV).

As of June 2026, the HTA Center of the Västra Götaland Region in Sweden is conducting six health technology assessments across areas such as gynecology, orthopedics, neurology, and in-vitro diagnostics.

Between January 1 and June 1, 2026, seven MedTech-related mini-HTAs were initiated in Norway across orthopedics, neurology and rehabilitation, in vitro diagnostics, interventional radiology, diagnostic imaging, and e-health. These assessments are conducted as part of Norway’s framework for the managed introduction of innovations, known as “New Methods”.

On June 2, 2026, the Decision of the National Union of Health Insurance Funds (UNCAM) updating the Nomenclature of Medical Biology Procedures (NABM) was released. The NABM is France’s primary permanent reimbursement catalog for in-vitro diagnostic tests covered under statutory health insurance. The update introduces regular reimbursement for four new codes, including two next-generation sequencing (NGS) panels that were previously covered temporarily under the innovative payment scheme (RIHN framework).

On June 2, 2026, OAAT AG and the tariff partners submitted the 2027 revision of the new Swiss comprehensive outpatient reimbursement system to the Federal Council for approval. The revision further develops the new system introduced in January 2026, incorporating feedback from the annual application process and focusing on updates to outpatient flat rates and TARDOC across nuclear medicine, surgery, pathology, pediatrics, and emergency care. If approved, the revised version will take effect on January 1, 2027.

The Agency for Health Technology Assessment and Tariff System (AOTMiT) initiated seventeen new health technology assessments in Poland in the second quarter of 2026. The assessments mainly cover cardiovascular medicine, diagnostic imaging, e-health, in-vitro diagnostics, pulmonology, and neurology.